clinical trial · NCT06475846
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
Fujian Shengdi Pharmaceutical Co., Ltd.·phase2·completed·n = 235
Preventing of Postoperative Nausea and Vomiting in AdultsHRS5580HRS5580HRS5580Ondansetronblank preparation
brief summary
The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.
started
Jun 25, 2024
primary completion
Oct 29, 2024
completion
Oct 29, 2024
last updated
Jan 20, 2025
official title
A Evaluate HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Efficacy and Safety of Ⅱ Period, Randomized, Multicenter, Dose of Exploration, Positive Control, Placebo-controlled, Double-blind, Double Simulation Trials
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol